Notice of Special Interest: Alzheimer's-focused administrative supplements for NIH grants that are not focused on Alzheimer's disease (NOT-AG-20-034)
Multiple Institutes, Including the NCI

Notice of Special Interest: Advancing the Science of Geriatric Palliative Care (NOT-AG-20-041)
Multiple Institutes, Including the NCI

Notice of FY2021 Cohort Dates for PA-19-029, Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial Not Allowed) (NOT-CA-20-106)
National Cancer Institute

Notice of Correction to PAR-20-295 “Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensitive Cancer Detection In Vivo (R01 Clinical Trials optional), National Cancer Institute

Request for Information (RFI): Pediatric preclinical models (cell lines and patient-derived xenografts) for which genomic characterization will enhance research value (NOT-CA-20-108), National Cancer Institute

Clarification of the Role of the Intramural Investigator in PAR-18-950 and PAR-18-951 “Opportunities for Collaborative Research at the NIH Clinical Center (X02 and U01) (NOT-HD-20-029)
Multiple Institutes, Including the NCI

Notice of Special Interest (NOSI): Research in the Emergency Setting (NOT-NS-20-005)
Multiple Institutes, Including the NCI

Reminder: NIH Policy on Use of Hypertext in NIH Grant Applications (NOT-OD-20-174)
National Institutes of Health
OCTOBER DEADLINES

Program Announcements

PA-17-460
"Multiple Institutes, including the NCI"
Biology of Lung, and Head and Neck Preneoplasias (R21 - Clinical Trial Not Allowed)
Deadline: 10/16/2020
About: This Funding Opportunity Announcement (FOA) seeks applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers. Despite improved therapies and a deeper molecular understanding of lung and HN cancers, these tumors remain a major health problem in the United States and globally.
Period of Support: Up to 2 years
Funds/Direct Costs: Application budgets are limited to $275,000 in direct costs per year
Program Contact: Long Nguyen
(240) 276-5807
long.nguyen@nih.gov

PA-18-720
"Multiple Institutes, including the NCI"
Exploratory/Developmental Clinical Research Grants in Obesity (R21 Clinical Trial Optional)
Deadline: 10/16/2020
About: This Funding Opportunity Announcement (FOA) encourages research grant applications from institutions/organizations that propose to conduct exploratory/developmental clinical studies that will accelerate the development of effective interventions for prevention or treatment of overweight or obesity in adults and/or children.
Period of Support: Up to 2 years
Funds/Direct Costs: Application budgets are limited to $275,000 in direct costs per year
Program Contact: Tanya Agurs-Collins
(240) 276-6956
collinsta@mail.nih.gov

PA-18-739
"Multiple Institutes, including the NCI"
Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R21 Clinical Trial Optional)
Deadline: 10/16/2020
About: The overall purpose of this funding opportunity announcement (FOA) is to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as relate to health and disease.
Period of Support: Up to 2 years
Funds/Direct Costs: The combined budget for direct costs for the two-year project period may not exceed $275,000.
Program Contact: Kaye Miles
(301) 827-4886
ekaye.miles@nih.gov

PA-18-943
"Multiple Institutes, including the NCI"
Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional)
Deadline: 10/16/2020
About: The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on the biobehavioral basis of chronic pain. The focus encompasses the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that underpin the individual’s chronic pain experience.
Period of Support: 2 years
Funds/Direct Costs: $275,000 direct costs for entire period of support
Program Contact: Sean Hine
(240) 276-6291
hines@mail.nih.gov

PA-19-111
National Cancer Institute
Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21)
Deadline: 10/16/2020
About: This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes.
Period of Support: Up to 2 years
**Funds/Direct Costs:** The combined budget for direct costs for the entire project period may not exceed $275,000.

**Program Contact:** Nonniekaye Shelburne  
(240) 276-6897  
nshelburne@mail.nih.gov

---

**PA-19-117**

"Multiple Institutes, including the NCI"

**Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)**

**Deadline:** 10/12/2020  

**About:** The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Award budgets are composed of salary and other program-related expenses, as described in announcement.

**Program Contact:** Susan Lim  
(240) 276-5588  
lims@mail.nih.gov

---

**PA-20-187**

"Multiple Institutes, including the NCI"

**NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)**

**Deadline:** 10/12/2020  

**About:** This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** K99 Phase: Up to $100,000/year salary + fringe, up to $30,000/year research expenses. R00 Phase: Up to $249,000/year

**Program Contact:** Michael Schmidt  
(240) 276-5630  
mschmidt@mail.nih.gov

---

**PA-20-188**

"Multiple Institutes, including the NCI"

**NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)**

**Deadline:** 10/12/2020  

**About:** This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** K99 Phase: Up to $100,000/year salary + fringe, up to $30,000/year research expenses. R00 Phase: Up to $249,000/year

**Program Contact:** Michael Schmidt  
(240) 276-5630  
mschmidt@mail.nih.gov

---

**PA-20-197, 198, 199**

"Multiple Institutes, including the NCI"

**Mentored Quantitative Research Development Award**

**Deadline:** 10/12/2020  

**About:** The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** K99 Phase: Up to $100,000/year salary + fringe, up to $30,000/year research expenses. R00 Phase: Up to $249,000/year

**Program Contact:** Michael Schmidt  
(240) 276-5630  
mschmidt@mail.nih.gov
About: The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research.

Period of Support: Up to 5 years
Funds/Direct Costs: Salary support up to $100,000 per year plus fringe benefits; research support up to $50,000 per year
Program Contact: Sonia B. Jakowlew
jakowles@mail.nih.gov

PA-20-201, 202, 203
"Multiple Institutes, including the NCI"
Mentored Clinical Scientist Research Career Development Award
Deadline: 10/12/2020
About: The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.

Period of Support: Up to 5 years
Funds/Direct Costs: Salary support plus fringe benefits; research support up to $50,000 per year
Program Contact: Susan Lim
lims@mail.nih.gov

PA-20-227
"Multiple Institutes, including the NCI"
Administrative Supplements for Research on Dietary Supplements
Deadline: 10/15/2020
About: This Funding Opportunity Announcement (FOA) announces the availability of administrative supplements to support research in which the supplemental funding would investigate the role of dietary supplements and/or their ingredients in health maintenance and disease prevention. Parent awards need not be focused on dietary supplements; this FOA may provide support to include dietary supplements within the scope of relevant research projects.

Period of Support: 1 year
Funds/Direct Costs: Budget requests may be for no more than $100,000 direct costs.
Program Contact: Sharon Ross
(240) 276-7124
rosssha@mail.nih.gov

PA-20-252
"Multiple Institutes, including the NCI"
Validation Studies of Analytical Methods for Dietary Supplement Constituents (Admin Supp - Clinical Trial Not Allowed)
Deadline: 10/15/2020
About: The rigor and reproducibility of research on dietary supplements are enhanced by rigorous characterization of key experimental resources and biological samples. The dissemination of analytical methods that are validated to accurately and reliably characterize dietary supplements and quantify their constituents and/or metabolites is vital for both basic and clinical research. This FOA builds on existing NIH awards to support the performance and publication of formal single-laboratory validation studies of analytical methods for dietary supplements and other natural products.

Period of Support: 1 year
Funds/Direct Costs: Application budgets are limited to no more than 25% of the Council-approved direct costs for the current budget year of the project or $100,000 (direct costs), whichever is less
Program Contact: Nancy J. Emenaker
(240) 276-7125
emenaker@mail.nih.gov

PAR-18-317
National Cancer Institute
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
Deadline: 10/08/2020
About: The purpose of this Funding Opportunity Announcement (FOA) is to support the validation of
molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control.  

**Period of Support:** Up to 3 years  
**Funds/Direct Costs:** Applicants may request up to $275,000 direct costs for the entire UH2 phase with no more than $200,000 requested in any one year and up to $250,000 direct costs for the UH3 phase per year.  
**Program Contact:** Tracy G. Lively  
(240) 276-5944  
livelyt@mail.nih.gov

**PAR-18-336**  
National Cancer Institute  
NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Clinical Trial Required)  
**Deadline:** 10/12/2020  

**About:** The purpose of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. The NCI-sponsored K08 award is specifically designed to promote career development of clinical scientists from backgrounds that have been shown to be nationally underrepresented in health-related science and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding.  

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Award budgets are composed of salary and other program-related expenses  
**Program Contact:** John O. Ojeifo  
(240) 276-6186  
ojeifojo@mail.nih.gov

**PAR-18-337**  
National Cancer Institute  
NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 No Clinical Trial Required)  
**Deadline:** 10/12/2020  

**About:** he purpose of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. The NCI-sponsored K08 award is specifically designed to promote career development of clinical scientists from backgrounds that have been shown to be nationally underrepresented in health-related science and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding.  

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Award budgets are composed of salary and other program-related expenses  
**Program Contact:** John O. Ojeifo  
(240) 276-6186  
ojeifojo@mail.nih.gov

**PAR-18-364**  
National Cancer Institute  
NCI Mentored Research Scientist Development Award to Promote Diversity (K01 -Independent Clinical Trial Not Allowed)  
**Deadline:** 10/12/2020  

**About:** The purpose of the NCI Mentored Research Scientist Development Award (K01) is to enhance the diversity of the pool of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor.  

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Award budgets are composed of salary and other program-related expenses  
**Program Contact:** Mulualem E. Tilahun  
(240) 276-7360
PAR-18-365
National Cancer Institute
NCI Mentored Research Scientist Development Award to Promote Diversity (K01 - Clinical Trial Required)
Deadline: 10/12/2020
About: The purpose of the NCI Mentored Research Scientist Development Award (K01) is to enhance the diversity of the pool of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of “protected time” for intensive research career development under the guidance of an experienced mentor.
Period of Support: Up to 5 years
Funds/Direct Costs: Award budgets are composed of salary and other program-related expenses
Program Contact: Mulualem E. Tilahun
(240) 276-7360
mulualem.tilahun@nih.gov

PAR-18-366
National Cancer Institute
NCI Transition Career Development Award to Promote Diversity (K22 No Independent Clinical Trials)
Deadline: 10/12/2020
About: The purpose of the NCI Transition Career Development Award to Promote Diversity is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist.
Period of Support: Up to 3 years
Funds/Direct Costs: Award budgets are composed of salary and other program-related expenses, as described in announcement.
Program Contact: Abigail Soyombo
(240) 276-6553
Abigail.Soyombo@nih.gov

PAR-18-367
National Cancer Institute
NCI Transition Career Development Award to Promote Diversity (K22 Clinical Trial Required)
Deadline: 10/12/2020
About: The purpose of the NCI Transition Career Development Award to Promote Diversity is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist.
Period of Support: Up to 3 years
Funds/Direct Costs: Award budgets are composed of salary and other program-related expenses
Program Contact: Mulualem E. Tilahun
(240) 276-7360
mulualem.tilahun@nih.gov

PAR-18-467
National Cancer Institute
The NCI Transition Career Development Award (K22 Clinical Trial Not Allowed)
Deadline: 10/12/2020
About: This Funding Opportunity Announcement (FOA) supports an NCI program that facilitates the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions.
Period of Support: Up to 3 years
Funds/Direct Costs: Application budgets are composed of salary and other program-related expenses as described in announcement.
Program Contact: Sonia Jakowlew
(240) 276-5630
jakowles@mail.nih.gov

PAR-18-857
"Multiple Institutes, including the NCI"
Diet and Physical Activity Assessment Methodology (R21 Clinical Trial Not Allowed)
Deadline: 10/16/2020
About: This Funding Opportunity Announcement (FOA) encourages innovative research to enhance the quality of measurements of dietary intake and physical activity.
Period of Support: Up to 2 years
Funds/Direct Costs: Direct costs are limited to $275,000 per year
Program Contact: Carol Perry
(240) 276-6282
perryc@nci.nih.gov

PAR-18-892
National Cancer Institute
Physical Activity and Weight Control Interventions Among
**Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21)**

**Deadline:** 10/16/2020


**About:** This Funding Opportunity Announcement (FOA) encourages transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available.

**Period of Support:** 2 years

**Funds/Direct Costs:** $275,000 direct costs for entire period of support

**Program Contact:** Frank Perna  
(240) 276-6782  
pernafm@mail.nih.gov

---

**PAR-19-044**

"Multiple Institutes, including the NCI"

End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R21)

**Deadline:** 10/16/2020


**About:** The purpose of this funding opportunity announcement (FOA) is to stimulate research to examine the multi-dimensional foundations, experiences and management of complex, advanced signs and symptoms at the end of life.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** $275,000 direct costs for entire period of support

**Program Contact:** Karen Kehl  
(301) 594-8010  
kehlka@nih.gov

---

**PAR-19-149**

"Multiple Institutes, including the NCI"

Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)

**Deadline:** 10/16/2020


**About:** The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** Application budgets are limited to $275,000 in direct costs per year

**Program Contact:** Miguel R. Ossandon  
(240) 276-5714  
ossandom@mail.nih.gov

---

**PAR-19-150**

National Cancer Institute

Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)

**Deadline:** 10/16/2020


**About:** The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of Exploratory/Developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.

**Program Contact:** Miguel R. Ossandon  
(240) 276-5714  
ossandom@mail.nih.gov

---

**PAR-19-163**

"Multiple Institutes, including the NCI"

Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)

**Deadline:** 10/16/2020


**About:** This FOA will support activities proposing to conduct analyses of existing ABCD Study data to accelerate the pace of research on child health and development, including: cross-sectional and/or longitudinal analyses; development of new or advanced statistical methods; and/or integration of multiple data sets with common data elements. Existing opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.
data provide unique opportunities to answer novel research questions in a cost-effective way. We also strongly encourage inclusion of statisticians, computational neuroscientists, and interdisciplinary teams to address novel research questions using these data.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.

**Program Contact:** Crystal Wolfrey  
(240) 276-6277  
wolfreyc@mail.nih.gov

---

**PAR-19-194**  
National Cancer Institute  
**Microbial-based Cancer Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)**  
**Deadline:** 10/16/2020  
**About:** The overall purpose of this funding opportunity announcement (FOA) is to stimulate exploratory development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. The FOA also aims to support research into the use of microorganisms for cancer treatment and to complement or synergize with current therapies.

**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** Application budgets are limited to $275,000 per year.

**Program Contact:** Avi Rasooly  
(240) 276-6196  
rasoolya@mail.nih.gov

---

**PAR-19-277**  
National Cancer Institute  
**Exploratory Grants in Cancer Epidemiology (R21 Clinical Trial Optional)**  
**Deadline:** 10/08/2020  
**About:** This funding opportunity announcement (FOA) encourages the submission of exploratory/developmental research grant (R21) applications for cancer epidemiologic research. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as improving data collection methods, developing and validating methods of exposures and biological effects, such as epigenetics and metabolomics, and their application in population-based research, functional assessment of genetic variants, and assessing recruitment methods for understudied populations.

**Period of Support:** 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.

**Program Contact:** Mukesh Verma  
(240) 276-6889  
vermam@mail.nih.gov

---

**PAR-19-309**  
National Cancer Institute  
**Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)**  
**Deadline:** 10/16/2020  
**About:** The purpose of this FOA is to provide support for the development of innovative interventions that improve cancer-related health behaviors in a variety of settings (e.g., families, communities, and health care delivery settings) across diverse racial/ethnic populations. The aim is to address one or more cancer-related behavioral risk factors to reduce cancer risk and disease burden.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.

**Program Contact:** Tanya Agurs-Collins  
(240) 276-6956  
collinsta@mail.nih.gov

---

**PAR-19-340**  
National Cancer Institute  
**Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R01 Clinical Trial Optional)**  
**Deadline:** 10/14/2020  
**About:** This FOA encourages the integration of cognitive neuroscience approaches to improve traditional assessment of acute and chronic cognitive changes following cancer treatment for non-central nervous system malignancies.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Todd S Horowitz  
(240) 276-6963  
todd.horowitz@mail.nih.gov

---

**PAR-19-350**  
National Cancer Institute
Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)
**Deadline:** 10/14/2020

**About:** Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication pilot interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels.

**Period of Support:** 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the 2-year project period may not exceed $275,000.

**Program Contact:** Kelly D. Blake  
(240) 281-5934  
kelly.blake@nih.gov

PAR-19-354
National Cancer Institute
Neural Regulation of Cancer (R01 Clinical Trial Not Allowed)
**Deadline:** 10/21/2020

**About:** This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer research elements, which together will advance our current understanding of the nervous system's contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Chamelli Jhappan  
(240) 276-6200  
jhappanc@mail.nih.gov

PAR-19-356
National Cancer Institute
NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
**Deadline:** 10/20/2020


**About:** This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; innovative preclinical studies, including the use of new clinically-relevant models and imaging technologies, which could lead to first-in-human clinical trials, and therapeutic outcome disparities, including biomarkers or genetic/epigenetic signatures, among diverse racial/ethnic populations, including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines.

**Period of Support:** 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

**Program Contact:** William Timmer  
(240) 276-6130  
william.timmer@nih.gov

PAR-19-389
National Cancer Institute
Perception and Cognition Research to Inform Cancer Image Interpretation (R21)
**Deadline:** 10/16/2020

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** $275,000 direct costs for entire period of support

**Program Contact:** Todd Horowitz  
(240) 276-6963  
todd.horowitz@nih.gov

PAR-20-052
National Cancer Institute
NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional)
**Deadline:** 10/20/2020
invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. Applications may propose studies using either single or mixed methods. Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.

**Period of Support:** 3-5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Charlisse Caga-Anan  
(240) 276-6738  
charlisse.caga-anan@nih.gov

---

**PAR-20-257**  
"Multiple Institutes, including the NCI"  
Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional)  
Deadline: 10/19/2020  

**About:** This Funding Opportunity Announcement (FOA) invites Small Research Grant (R03) applications to study the
ethical, legal and social implications (ELSI) of human genome research. These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data.

**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** Application budgets are limited to no more than $50,000 in direct costs per year.  
**Program Contact:** Charlisse Caga-Anan  
(240) 276-6738  
charlisse.caga-anan@nih.gov

---

**PAR-20-277**  
"Multiple Institutes, including the NCI"  
**Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)**  
**Deadline:** 10/16/2020  
**About:** Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer genomic and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants are encouraged to leverage existing genetic data and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in genomic and epidemiology cancer research.  
**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** Direct costs are limited to $275,000 over a two-year project period, with no more than $200,000 in direct costs allowed in any single year.  
**Program Contact:** Lisa Gallicchio  
(240) 276-5741  
Lisa.gallicchio@nih.gov

---

**PAR-20-281**  
"Multiple Institutes, including the NCI"  
**Fertility Status as a Marker for Overall Health (R01 Clinical Trial Optional)**  
**Deadline:** 10/19/2020  
**About:** The purpose of this funding opportunity (FOA) is to support research that explores the premise that fertility status can be a marker for overall health. Chronic conditions such as cancer, diabetes, and obesity can impair fertility; however, less is known about the extent to which fertility status can impact or act as a marker for overall health. Data suggest that infertility is not necessarily a unique disease of the reproductive axis but is often physiologically or genetically linked with other diseases and conditions. Recent epidemiologic studies demonstrate links between fertility status in both males and females and various somatic diseases and disorders. Taken together, these data strongly suggest that fertility status can be a window into overall health. Advancing this premise will require substantive involvement of experts in reproductive health/fertility along with expert in another non-reproductive specialty appropriate to the area of overall health being investigated, for example, in other fields such as epidemiology, or the somatic disease in question. This FOA focuses on studies evaluating fertility as a marker for overall health, and therefore applications that look at the effects of the disease or disorder on fertility are outside of the scope of this program. Recruitment of new cohorts will not be supported by this FOA.  
**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.  
**Program Contact:** Melissa Rotunno  
(240) 276-7245  
rotunnom@mail.nih.gov

---

**PAR-20-282**  
"Multiple Institutes, including the NCI"  
**Fertility Status as a Marker for Overall Health (R21 Clinical Trial Not Allowed)**  
**Deadline:** 10/19/2020  
**About:** The purpose of this funding opportunity announcement (FOA) is to support exploratory/developmental research that explores the premise that fertility status can be a marker for overall health. Chronic conditions such as cancer, diabetes, and obesity can impair fertility; however, less is known about...
the extent to which fertility status can impact or act as a marker for overall health. Data suggest that infertility is not necessarily a unique disease of the reproductive axis but is often physiologically or genetically linked with other diseases and conditions. Recent epidemiologic studies demonstrate links between fertility status in both males and females and various somatic diseases and disorders. Taken together, these data strongly suggest that fertility status can be a window into overall health. Advancing this premise will require substantive involvement of experts in reproductive health/fertility along with expert in another non-reproductive specialty appropriate to the area of overall health being investigated, for example, experts in other fields such as epidemiology, or the somatic disease in question. This FOA focuses on studies evaluating fertility as a marker for overall health, and therefore applications that look at the effects of a disease or disorder on fertility are outside of the scope of this program. Recruitment of new cohorts will not be supported by this FOA.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

**Program Contact:** Lisa Gallicchio  
(240) 276-5741  
Lisa.gallicchio@nih.gov

---

**PAR-20-292**

**National Cancer Institute**

**NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)**

**Deadline:** 10/20/2020  

**About:** This Funding Opportunity Announcement (FOA) supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer health disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among diverse racial/ethnic populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based on established mechanisms of action. Comparative oncology studies in dogs investigating strategies for treatment and diagnosis of human disease are supported as well.

**Period of Support:** Up to 2 years.

**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

**Program Contact:** Morgan O’Hayre  
(240) 276-7482  
ohayrem@mail.nih.gov

---

**Request for Applications (RFA)**

**RFA-CA-19-049**

**National Cancer Institute**

**Revision Applications for Mechanisms of Cancer Drug Resistance (R01 Clinical Trial Not Allowed)**

**Deadline:** 10/22/2020  

**About:** The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded R01 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target
resistant/refractory tumors and/or their microenvironment at the clinical level.

**Period of Support**: Up to 3 years, not to exceed the remaining number of years on the parent grant

**Funds/Direct Costs**: Application budgets may not exceed $250,000 Direct Costs per year.

**Program Contact**: Laurence (Austin) Doyle  
(240) 276-6112  
Doyuela@mail.nih.gov

---

**RFA-CA-20-040**  
"Multiple Institutes, including the NCI"  
**Aging, Cancer-Initiating Cells, and Cancer Development (U01 Clinical Trial Not Allowed)**

**Deadline**: 10/27/2020  

**About**: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) and National Institute on Aging (NIA) will promote research to advance the understanding of the mechanistic factors and cellular interactions during aging that contribute to cancer initiation. Collaborations are strongly encouraged between scientists in the fields of aging biology and cancer biology. Applications should address key questions regarding how hallmarks of aging that lead to impaired cellular activities (metabolic alterations, proteostasis, epigenetic changes, and DNA repair) and alterations in the microenvironment (inflammation and immunosenescence) contribute to the development and outgrowth of cancer-initiating cells.

**Period of Support**: Up to 5 years

**Funds/Direct Costs**: Award budgets are limited to $300,000 per year in direct costs and must reflect the actual needs of the proposed project.

**Program Contact**: Margaret Klauzinska  
(240) 276-5181  
klauzing@mail.nih.gov

---

**RFA-CA-20-044**  
National Cancer Institute  
**Visualization Methods and Tools Development for Enhancing Cancer Moonshot Data (R33 Clinical Trial Not Allowed)**

**Deadline**: 10/30/2020  

**About**: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the development of new cancer data visualization methods and tools that have the potential to make data aligned with the Cancer Moonshot more explorable and interpretable by the broader cancer research community. This FOA supports the development of new, full-featured data visualization tools for investigator-specified, Moonshot-aligned use cases that enable a broader community of users to explore and gain insights from data emerging from or aligned with one or more of the Cancer Moonshot areas.

**Period of Support**: Up to 4 years

**Funds/Direct Costs**: Application budgets must reflect the actual needs of the proposed project but must not exceed $250,000 per year in direct costs.

**Program Contact**: David J. Miller  
(240) 276-6810  
david.miller3@nih.gov

---

**RFA-HG-20-048**  
"Multiple Institutes, including the NCI"  
**Investigator-Initiated Research on Genetic Counseling Processes and Practices (R01 Clinical Trial Optional)**

**Deadline**: 10/28/2020  

**About**: The purpose of this initiative is to support investigator-initiated research on genetic counseling processes and practices in genomic medicine. Research is needed to optimize the genetic counseling process in the context of limited resources. Applications will assess, innovate, scale, and/or research the implementation of novel genetic counseling practices to address the need for more healthcare professionals trained in genetic counseling; the uneven access to in-person genetic counseling across U.S. health care systems; and the challenges of effective and efficient communication of genomic findings to clinicians, patients, and families.

**Period of Support**: Up to 4 years

**Funds/Direct Costs**: Application budgets are limited to $500,000 direct costs/year.

**Program Contact**: Leah Mechanic  
(240) 276-6847  
mechanil@nci.nih.gov

---

**RFA-DA-21-009**  
"Multiple Institutes, including the NCI"  
**Interventions to Prevent Electronic Nicotine Delivery Systems (ENDS) Use Among Adolescents (R01 - Clinical Trial Optional)**

**Deadline**: 10/19/2020  

**About**: The purpose of this funding opportunity announcement is to support (1) research to test the efficacy or effectiveness of interventions to prevent initiation and/or escalation of ENDS (electronic nicotine delivery system) use among adolescents; and (2) research on the impact of tobacco control policies, including ENDS-specific policies, on adolescent ENDS use behavior. Of priority is
research that is theoretically based and identifies specific risk and protective factors to target through prevention intervention, or research on policies that can impact adolescent ENDS use. Particularly, for prevention intervention research (e.g., school, community, and clinic-based), collaboration with stakeholders and likely program adopters is required to ensure feasibility for implementation, scalability, dissemination and sustainability. For this funding announcement, individuals as young as 12 and as old as 18 encompass the core target age range. Justification for the specific age or age range of the target population is required, including studies that propose targeting youth outside the core age range.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are limited to $500,000 direct costs per year.  
**Program Contact:** Rachel Grana Mayne  
(240) 276-5899  
Rachel.Mayne@nih.gov

---

**RFA-EB-18-003**  
"Multiple Institutes, including the NCI"  
**HEAL Initiative: Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed)**  
**Deadline:** 10/21/2020  
**About:** The purpose of this Funding Opportunity Announcement (FOA) is to support preclinical development and demonstration of safe, effective, and non-addictive device-based technologies and approaches to treat pain. The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain.  
**Period of Support:** Up to 3 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project. Budgets should rarely exceed $500,000 direct cost per year.  
**Program Contact:** Diane St. Germain  
(240) 276-7082  
dstgermain@mail.nih.gov

---

**Program Announcements**

**PAR-18-654**  
National Cancer Institute  
**Basic Research in Cancer Health Disparities (R01)**  
**Deadline:** 11/19/2020  
**About:** This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities.  
**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.  
**Program Contact:** Jennifer Isaacs  
(240) 276-6251  
jennifer.isaacs@nih.gov

---

**PAR-18-731**  
National Cancer Institute  
**Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21)**  
**Deadline:** 11/19/2020  

---

**NOVEMBER/DECEMBER DEADLINES**

**Foundation and Other Sources**

**The Elsa U. Pardee Foundation Cancer Research Grant**

---

**Deadline:** 12/31/2020  
https://pardeefoundation.org/how-to-apply/  
**About:** The Elsa U. Pardee Foundation funds research to investigators in United States non-profit institutions proposing research directed toward identifying new treatments or cures for cancer. The Foundation funds projects for a one year period which will allow establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers. It is anticipated that this early stage funding by the Foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified. By design, there are no limits set on the grant amount that can be requested. It must be reasonably and clearly supported by the scope of the project outlined in the application. Applications requesting more than 5% overhead are usually not considered. Papers verifying nonprofit status and relevant human subject and experimental animal treatment approvals from the recipient institution will be requested prior to project initiation. A final report summarizing financial expenditure and research achievement is required.  
**Period of Support:** 1 year  
**Funds/Direct Costs:** No Limit  
**Program Contact:** Award Programs  
(989) 832-3691

---

**MCC Research Administration**  
October 2020 Funding Newsletter  
Page 14 of 27
About: This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to enhance the diversity of the pool of the cancer research workforce by recruiting and supporting eligible junior investigators and Early Stage Investigators from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, clinical and social sciences.

Period of Support: Up to 2 years
Funds/Direct Costs: $275,000 direct costs for entire period of support
Program Contact: Abigail Soyombo
(240) 276-6553
abigail.soyombo@nih.gov

PA-20-222
"Multiple Institutes, including the NCI"
Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)
Deadline: 12/1/2020

About: Funds are available for administrative supplements to enhance the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from diverse backgrounds, including those from groups that have been shown to be underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project.

Period of Support: The project and budget periods must be within the currently approved project period for the existing parent award.
Funds/Direct Costs: Direct costs for individual administrative supplements vary from less than $5,000 to more than $100,000 depending on the career level of the candidate.
Program Contact: Alison Lin
(240) 276-6177
linaj@mail.nih.gov

PAR-18-841
National Cancer Institute
Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24 - Clinical Trial Optional)
Deadline: 11/17/2020

About: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve the quality of imaging results for co-clinical trials.

Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets for direct costs up to $500,000 per year may be requested.
Program Contact: Nancy Boudreau
(240) 276-6702
nancy.boudreau@nih.gov

PAR-18-869
National Cancer Institute
Modular R01s in Cancer Control and Population Sciences (R01)
Deadline: 11/06/2020

About: This funding opportunity announcement (FOA) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.

Period of Support: Up to 5 years
Funds/Direct Costs: $250,000 direct costs per year
Program Contact: Scott Rogers
(240) 276-6932
rogerssc@mail.nih.gov
PAR-18-911
National Cancer Institute
Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20 Clinical Trial Not Allowed)
Deadline: 11/13/2020
About: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites P20 planning grant applications for developing collaborative partnership between institutions serving underserved health disparity populations and underrepresented students (ISUPS) and NCI- designated Cancer Centers (or Cancer Centers with highly integrated cancer research programs). This FOA is designed to facilitate the planning and execution of focused collaborations in cancer-related research, research experience, and research education.
Period of Support: Up to 4 years
Funds/Direct Costs: The combined budget of direct costs for ISUPS and CC cannot exceed $375,000 per year.
Program Contact: Behrous Davani
(240) 276-6098
behrous.davani@nih.gov

PAR-19-064
"Multiple Institutes, including the NCI"
Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)
Deadline: 11/6/2020
About: This Funding Opportunity Announcement (FOA) will support pilot, feasibility or exploratory research in 5 priority areas in substance use epidemiology and health services, including: 1) responses to sudden and severe emerging drug issues 2) responses to emerging marijuana trends and topics related to the shifting policy landscape; 3) responses to unexpected and time-sensitive prescription drug abuse research opportunities 4) responses to unexpected and time-sensitive medical system issues; and 5) responses to unexpected and time-sensitive criminal or juvenile justice that relate to drug abuse and access and provision of health care service.
Period of Support: Up to 2 years
Funds/Direct Costs: Direct costs are limited to $275,000
Program Contact: Kelly D. Blake
(240) 281-5934
kelly.blake@nih.gov

PAR-19-198
National Cancer Institute
Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R01 Clinical Trial Not Allowed)
Deadline: 11/6/2020
About: The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses. Thus, research projects should be focused on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Young S. Kim
(240) 276-7115
yk47s@nih.gov

PAR-19-199
National Cancer Institute
Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R21 Clinical Trial Not Allowed)
Deadline: 11/6/2020
About: The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses. Thus, research projects should be focused on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation.
Period of Support: Up to 2 years
Funds/Direct Costs: The combined budget for direct costs for the two-year project period may not exceed $275,000.
Program Contact: Young S. Kim
(240) 276-7115
yk47s@nih.gov

PAR-19-251
National Cancer Institute
Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention (R01 Clinical Trial Optional)
Deadline: 11/06/2020
About: The overall objective of this Funding Opportunity Announcement (FOA) is to support innovative research on adducts to cellular macromolecules as indicators of exposures to endogenous and exogenous cancer risk factors
relevant to exposures in human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. The ultimate goal is to discover and characterize the utility of adductomic-based exposure indicators for cancer detection, cancer prevention, and/or assessing cancer risks.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:**

Wendy Wang  
(240) 276-7117  
wangw@mail.nih.gov

---

**PAR-19-279**

National Cancer Institute  
**Profound Questions (PQs) in Multiple Myeloma Disparities Research (R01 Clinical Trial Optional)**

**Deadline:** 11/15/2020  

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to support new research projects designed to use sound and innovative strategies to solve specific problems and paradoxes in multiple myeloma disparities research identified by the National Cancer Institute (NCI) as the NCI’s Multiple Myeloma and Disparities Provocative Questions (MMD PQs).

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:**  
Amy Kennedy  
(240) 781-3335  
amy.kennedy@nih.gov

---

**PAR-19-287**

National Cancer Institute  
**Research Projects in Cancer Systems Biology (U01 Clinical Trial Optional)**

**Deadline:** 11/17/2020  

**About:** The National Cancer Institute’s (NCI) Cancer Systems Biology Consortium (CSBC) supports systems biology approaches to cancer research and includes US4 CSBC Research Centers, a U24 CSBC Coordinating Center and, through this FOA, well-defined, discrete and circumscribed U01 Research Projects. CSBC Research Projects are expected to involve interdisciplinary teams of scientists, engineers, and cancer researchers who collaborate to advance our understanding of the mechanisms underlying cancer initiation, progression, and treatment. CSBC Research Projects proposed in response to this Funding Opportunity Announcement must be based upon explicit integration of experimental biology and computational modeling to test and validate novel hypotheses in cancer research.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are limited to $400,000 in direct costs per year.

**Program Contact:** Shannon Hughes  
(240) 276-6224  
shannon.hughes@nih.gov

---

**PAR-19-361**

National Cancer Institute  
**Small Cell Lung Cancer (SCLC) Consortium: Biology, Therapy and Resistance (U01 Clinical Trial Not Allowed)**

**Deadline:** 11/12/2020  

**About:** This Funding Opportunity Announcement (FOA) invites applications for research projects to join the Small-Cell Lung Cancer (SCLC) Consortium. Goals of the SCLC Consortium pertinent to this FOA are: 1) to learn the mechanistic and biological underpinnings of SCLC formation, progression and heterogeneity; 2) to investigate how molecular vulnerabilities could be used to develop targeted agents or combinations; and 3) to understand clinical resistance to drug and radiation therapy and its rapid development.

**Period of Support:** 5 years

**Funds/Direct Costs:** Budgets are limited to $450,000 Direct Costs (excluding consortium F&A costs) per year.

**Program Contact:** Suzanne Forry  
(240) 276-5922  
forryscs@mail.nih.gov

---

**PAR-20-116**

National Cancer Institute  
**Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)**

**Deadline:** 11/19/2020  

**About:** This Funding Opportunity Announcement (FOA), entitled "Toward Translation of Cancer Nanotechnology Interventions (TTNCI)" is to enable the translation of nanotechnology-based cancer interventions relying on next-generation nanoparticle formulations and/or nano-devices. The TTNCI initiative encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. The "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI) awards are designed to mature experimental nanomedicines relying on "next-generation" nanoparticles and nano-devices which demonstrate strong
potential to improve treatment effectiveness and/or tackle cancers that currently have a very limited arsenal of approved therapies or diagnostic strategies. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.

**Period of Support:** Up to 4 years

**Funds/Direct Costs:** Application budgets are limited to $475,000 in direct costs per year and need to reflect the actual needs of the proposed project

**Program Contact:** Piotr Grodzinski
(240) 781-3305
grodzinp@mail.nih.gov

---

**PAR-20-170**

National Cancer Institute

**New Informatics Tools and Methods to Enhance U.S. Cancer Surveillance Research (U01 Clinical Trial Optional)**

**Deadline:** 11/18/2020


**About:** The goal of this Funding Opportunity Announcement (FOA) is to advance surveillance science by supporting the development of new and innovative tools and methods for more efficient, detailed, timely, and accurate data collection by cancer registries. Specifically, the FOA solicits applications for projects to develop, adapt, apply, scale-up, and validate tools and methods to improve the collection and integration of cancer registry data to expand the data items collected. Applications proposed must be based on partnership with at least two U.S. population-based central cancer registries. Tools and methods proposed for development are expected to enhance the registry core infrastructure and, in so doing, expand the usefulness of registry-collected data to support high-quality cancer research.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Nadia Howlader
(240) 276-6891
howladern@mail.nih.gov

---

**PAR-20-278**

National Cancer Institute

**NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed)**

**Deadline:** 11/06/2020


**About:** The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for the NCI OIA.

**Period of Support:** Up to 7 years

**Funds/Direct Costs:** Awards will be for $600,000 direct costs per year.

**Program Contact:** Christine Siemon
(240) 276-6266
siemonc@nih.gov

---

**PAR-20-284**

National Cancer Institute

**Innovative Research in Cancer Nanotechnology (IRCN)**

(R01 Clinical Trial Not Allowed)

**Deadline:** 11/04/2020


**About:** This Funding Opportunity Announcement (FOA) entitled "Innovative Research in Cancer Nanotechnology (IRCN)" encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address major barriers in cancer biology and/or oncology using nanotechnology and should focus on mechanistic studies to expand the fundamental understanding of nanomaterial and/or nano-device interactions with biological systems. These studies are expected to be relevant to the delivery of nanoparticles and/or nano-devices to desired and intended cancer targets in vivo and/or characterization of detection and diagnostic devices and sensors in vitro. IRCN awards are expected to produce fundamental knowledge to aid future and more informed development of nanotechnology-based cancer interventions.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are limited to $450K in direct costs per year and need to reflect the actual needs of the proposed project.

**Program Contact:** Piotr Grodzinski
(240) 781-3305
grodzinp@mail.nih.gov

---

**PAR-20-294**

National Cancer Institute

**Core Infrastructure Support for Cancer Epidemiology Cohorts (U01 Clinical Trial Not Allowed)**

**Deadline:** 11/12/2020

MCC Research Administration
October 2020 Funding Newsletter
Page 18 of 27
Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages grant applications for support of the core functions of Cancer Epidemiology Cohorts (CECs), as well as methodological research. This FOA is intended to support the maintenance of existing CECs infrastructure and resource sharing with broader scientific communities.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Joanne Elena  
(240) 276-6818  
joanne.elena@nih.gov

---

**PAR-20-302**

"Multiple Institutes, including the NCI"

**Tobacco Control Policies to Promote Health Equity (R01 Clinical Trial Optional)**

**Deadline:** 11/12/2020  

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing disparities in tobacco use and secondhand smoke (SHS) exposure in the U.S. Specifically, this FOA aims to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of this FOA is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations. Applicants submitting applications related to health economics are encouraged to consult NOT-OD-16-025 to ensure that the research projects align with NIH mission priorities in health economics research.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Bob Vollinger  
(240) 276-6919  
Bob.Vollinger@nih.gov

---

**PA-19-188**

"Multiple Institutes, including the NCI"

**Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)**

**Deadline:** 12/08/2020  

**About:** The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32) is to support research training of highly promising postdoctoral candidates who have the potential to become productive, independent investigators in scientific health-related research fields relevant to the missions of the participating NIH Institutes and Centers. Applications are expected to incorporate exceptional mentorship.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** See announcement for details.

**Program Contact:** Nicole Jones  
(240) 276-7156  
jonesni@mail.nih.gov

---

**PA-19-195**

"Multiple Institutes, including the NCI"

**Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)**

**Deadline:** 12/08/2020  

**About:** The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31) is to enable promising predoctoral students to obtain individualized, mentored research training from outstanding faculty sponsors while conducting dissertation research in scientific health-related research areas.
fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training must reflect the applicant's dissertation research project and is expected to clearly enhance the individual's potential to develop into a productive, independent research scientist.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** See announcement for details.  
**Program Contact:** Nicole Jones  
(240) 276-7156  
jonesni@mail.nih.gov

---

**PA-20-196**  
"Multiple Institutes, including the NCI"  
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31)  
**Deadline:** 12/08/2020  
**About:** The purpose of this Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research award is to enhance the diversity of the health-related research workforce by supporting the research training of predoctoral students from diverse backgrounds including those from groups that are underrepresented in the biomedical, behavioral, or clinical research workforce.  
**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** See announcement for details.  
**Program Contact:** Nicole Jones  
(240) 276-7156  
jonesni@mail.nih.gov

---

**PA-20-207**  
"Multiple Institutes, including the NCI"  
NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)  
**Deadline:** 12/12/2020  
**About:** The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers.  
**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The appropriate NIH Conference Grant Contact should be consulted for guidance regarding any IC-specific budget limitations.  
**Program Contact:** Christopher L. Hatch  
(240) 276-6454

---

**PA-20-242**  
"Multiple Institutes, including the NCI"  
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)  
**Deadline:** 12/08/2020  
**About:** The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32) is to support research training of highly promising postdoctoral candidates who have the potential to become productive, independent investigators in scientific health-related research fields relevant to the missions of the participating NIH Institutes and Centers. Applications are expected to incorporate exceptional mentorship.  
**Period of Support:** Up to 6 years  
**Funds/Direct Costs:** Award budgets are composed of stipends, tuition and fees, and institutional allowance.  
**Program Contact:** Sonia B. Jakowlew  
jakowles@mail.nih.gov

---

**PA-20-246**  
"Multiple Institutes, including the NCI"  
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)  
**Deadline:** 12/08/2020  
**About:** The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31) is to enable promising predoctoral students to obtain individualized, mentored research training from outstanding faculty sponsors while conducting dissertation research in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training must reflect the candidate’s dissertation research project and is expected to clearly enhance the individual's potential to develop into a productive, independent research scientist.  
**Period of Support:** Up to 6 years  
**Funds/Direct Costs:** Award budgets are composed of stipends, tuition and fees, and institutional allowance.  
**Program Contact:** Michael Schmidt  
(240) 276-5630  
mschmidt@mail.nih.gov

---

**PA-20-247**  
"Multiple Institutes, including the NCI"
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)
Deadline: 12/08/2020
About: The National Institutes of Health (NIH) awards senior individual research training fellowships to experienced scientists who wish to make major changes in the direction of their research careers or who wish to broaden their scientific background by acquiring new research capabilities as independent investigators in research fields relevant to the missions of participating NIH Institutes and Centers.
Period of Support: Up to 6 years
Funds/Direct Costs: Award budgets are composed of stipends, tuition and fees, and institutional allowance.
Program Contact: Sonia B. Jakowlew
jakowles@mail.nih.gov

PA-20-248
"Multiple Institutes, including the NCI"
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)
Deadline: 12/08/2020
About: This Funding Opportunity Announcement (FOA) will support students at institutions with NIH-funded institutional predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctoral fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g. DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), and who intend careers as physician/clinician-scientists. Candidates must propose an integrated research and clinical training plan and a dissertation research project in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The fellowship experience is expected to clearly enhance the individual's potential to develop into a productive, independent physician/clinician-scientist.
Period of Support: Up to 6 years
Funds/Direct Costs: Award budgets are composed of stipends, tuition and fees, and institutional allowance.
Program Contact: Mark Damico
damicomw@mail.nih.gov

PA-20-251
"Multiple Institutes, including the NCI"
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)
Deadline: 12/08/2020
About: The purpose of this Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research award is to enhance the diversity of the health-related research workforce by supporting the research training of predoctoral students from diverse backgrounds including those from groups that are underrepresented in the biomedical, behavioral, or clinical research workforce.
Period of Support: Up to 6 years
Funds/Direct Costs: Award budgets are composed of stipends, tuition and fees, and institutional allowance.
Program Contact: Peter Ogunbiyi
(240)-276-6170
ogunbiyp@mail.nih.gov

PAR-19-264
National Cancer Institute
Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer (R01 Clinical Trial Optional)
Deadline: 12/10/2020
About: This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that include imaging, biomarkers, digital pathomic and other -omic integration strategies for improving current approaches for the earliest detection of premetastatic aggressive cancer as well as identifying precancerous lesions that will subsequently demonstrate an aggressive phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions in a technology agnostic manner by improving sensitivity and specificity of applied tests.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Sudhir Srivastava
(240) 276-7028
srivasts@mail.nih.gov

Request for Applications (RFA)
RFA-CA-20-004
National Cancer Institute
Research Answers to National Cancer Institute's (NCI)
**Provocative Questions (R01 Clinical Trial Optional)**

**Deadline:** 11/17/2020  

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions Initiative. These problems and paradoxes, phrased as questions, are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Some of these "Provocative Questions" (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that have traditionally been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances. The current issuance of the PQ Initiative includes an updated set of 9 PQs. Each research project proposed in response to this FOA must be focused on addressing the research problems defined by a specific PQ selected from the list. Projects proposed to address PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged if they serve the scientific focus of the selected PQ.

**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year. Application budgets should reflect the actual needs of the proposed project.  
**Program Contact:** Sean Hanlon  
(240) 781-3310  
sean.hanlon@nih.gov

---

**RFA-CA-20-005**  
**National Cancer Institute**  
**Research Answers to National Cancer Institute’s (NCI) Provocative Questions (R21 Clinical Trial Optional)**  
**Deadline:** 11/17/2020  

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions Initiative. These problems and paradoxes, phrased as questions, are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Some of these "Provocative Questions" (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that have traditionally been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances. The current issuance of the PQ Initiative includes an updated set of 9 PQs. Each research project proposed in response to this FOA must be focused on addressing the research problems defined by a specific PQ selected from the list. Projects proposed to address PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged if they serve the scientific focus of the selected PQ.

**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year. Application budgets should reflect the actual needs of the proposed project.  
**Program Contact:** Sean Hanlon  
(240) 781-3310  
sean.hanlon@nih.gov

---

**RFA-CA-20-007**  
**National Cancer Institute**  
**Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)**  
**Deadline:** 11/18/2020  

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods that can considerably improve acquisition, management, analysis, and dissemination of relevant data and/or knowledge.

**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** Direct costs are limited to $275,000
About: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.

Period of Support: Up to 5 years

Funds/Direct Costs: Budgets are limited to $600,000 Direct Costs (excluding consortium F&A) per year.

Program Contact: Juli Klemm
(301) 480-5778
juli.klemm@nih.gov

RFA-CA-20-010
National Cancer Institute
Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
Deadline: 11/18/2020

About: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and
resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR FOAs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justification for why the research resource should be maintained and how it has benefitted and will continue to benefit the cancer research field. In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and deep engagement between the resource and the targeted research community should be described.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Juli Klemm  
(301) 480-5778  
juli.klemm@nih.gov

---

**RFA-CA-20-012**  
National Cancer Institute  
Revision Applications to Support the Application of Informatics Technology for Cancer Research (U24 Clinical Trial Optional)  
**Deadline:** 11/18/2020  

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U24 resource-related research projects. These revision applications can request support for expansion of the original scope of the parent study by incorporating informatics methods, tools or resources developed through current or previous support from the NCI Informatics Technology for Cancer Research (ITCR) Program. Awards from this FOA are meant to spur novel collaborations and to incentivize the adoption, adaptation, and integration of these informatics technologies in support of the appropriate research communities. As a component of the NCI ITCR program, this FOA aims to promote interdisciplinary collaboration in the adoption and enhancement of innovative informatics methods, tools, and resources that enable cancer research and accelerate scientific discovery.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** Application budgets may not exceed $100,000 in direct costs per year.

**Program Contact:** Juli Klemm  
(301) 480-5778  
juli.klemm@nih.gov

---

**RFA-CA-20-013**  
National Cancer Institute  
Revision Applications to Support the Application of Informatics Technology for Cancer Research (U01 Clinical Trial Optional)  
**Deadline:** 11/18/2020  

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects. These revision applications can request support for expansion of the original scope of the parent study by incorporating informatics methods, tools or resources developed through current or previous support from the NCI Informatics Technology for Cancer Research (ITCR) Program. Awards from this FOA are meant to spur novel collaborations and to incentivize the adoption, adaptation, and integration of these informatics technologies in support of the appropriate research communities. As a component of the
NCI ITCR program, this FOA aims to promote interdisciplinary collaboration in the adoption and enhancement of innovative informatics methods, tools, and resources that enable cancer research and accelerate scientific discovery.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** Application budgets may not exceed $100,000 in direct costs per year.

**Program Contact:** Juli Klemm
(301) 480-5778
juli.klemm@nih.gov

---

**RFA-CA-20-034**
National Cancer Institute
NCI Pediatric In Vivo Testing Program (U01 Clinical Trial Not Allowed)

**Deadline:** 11/09/2020

**About:** This Funding Opportunity Announcement (FOA) is for Research Teams to form the NCI Pediatric In Vivo Testing Program (henceforth termed the Ped-In Vivo-TP). The Research Teams of the Ped-In Vivo-TP will determine the activity of pediatric anticancer drug candidates using preclinical models relevant to the cancer(s) on which their team focuses (supported under this FOA) and will work in concert with the Ped-In Vivo-TP Coordinating Center (supported under RFA-CA-20-041). The Research Teams will use genomically characterized pediatric cancer models to develop a rigorous preclinical testing program that will generate reliable data that can be used to inform new agent prioritization decisions for childhood cancer clinical testing.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** The application budget is limited to $450,000 in direct costs per year and should reflect the actual needs of the project.

**Program Contact:** Malcolm A. Smith
(240) 276-6087
Malcolm.Smith@nih.gov

---

**RFA-CA-20-042**
National Cancer Institute
3D Technologies to Accelerate HTAN Atlas Building Efforts (UH2 Clinical Trial Not Allowed)

**Deadline:** 11/09/2020

**About:** The overarching goal of this FOA is to accelerate research efforts conducted and led by the Human Tumor Atlas Network (HTAN, humantumoratlas.org) via the implementation of three-dimensional (3D) imaging technologies that will allow for a comprehensive view of the dynamic multidimensional ecosystems that define tumors in humans.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** Application budgets are limited to $250,000 in direct cost per year and must reflect the actual needs of the proposed project.

**Program Contact:** Philipp Oberdoerffer
(240) 760-6681
Philipp.Oberdoerffer@nih.gov

---

**RFA-CA-20-047**
National Cancer Institute
Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)

**Deadline:** 11/19/2020

**About:** The overall goal of this funding opportunity announcement (FOA) is to improve the treatment of adult glioblastoma (GBM) by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them in the clinic. To implement this initiative, multi-institutional teams are invited to participate in the Glioblastoma Therapeutics Network (GTN). Each GTN team is expected to drive therapeutic agent(s) from pre-clinical development, through IND studies, into pilot clinical studies in humans.

**Period of Support:** 5 years

**Funds/Direct Costs:** Application budgets are limited to direct costs (DC) of $700,000 per year. If a Network Coordinating Center (NCC) component is proposed, an
additional $300,000 DC/year may be included.

**Program Contact:** Suzanne Forry  
(240) 276-5922  
forryscs@mail.nih.gov

---

**RFA-CA-20-048**  
*National Cancer Institute*  
**NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)**  
**Deadline:** 11/16/2020  
https://www.cancer.gov/grants-training/training/funding/f99

**About:** The purpose of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to encourage and retain outstanding graduate students recognized by their institutions for their high potential and strong interest in pursuing careers as independent cancer researchers. The award will facilitate the transition of talented graduate students into successful cancer research postdoctoral appointments, and provide opportunities for career development activities relevant to their long-term career goals of becoming independent cancer researchers. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

**Period of Support:** F99 phase: Up to 2 years K00 phase: Up to 4 years

**Funds/Direct Costs:** F99 phase: Stipend, Tuition and Fees, and Institutional Allowance  K00 phase: Salary and Fringe Benefits, Tuition and Fees, Research and Career Development Support, and Indirect Costs

**Program Contact:** Mariam Eljanne  
mariam.eljanne@nih.gov

---

**RFA-HD-21-002**  
*"Multiple Institutes, including the NCI" Centers to Advance Research in Endometriosis (CARE) (P01 Clinical Trial Not Allowed)*  
**Deadline:** 11/30/2020  

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to support the novel development of Centers to Advance Research in Endometriosis (CARE). These multidisciplinary programs will incorporate basic, translational, and/or clinical studies (excluding clinical trials) in a collaborative entity to accelerate research advances through sharing of knowledge and resources. The ultimate goal of the program is to improve female reproductive health through successful prevention and treatment of endometriosis.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets may request a budget for direct costs of no more than $1.0 million/year.

**Program Contact:** Goli Samimi  
(301) 276-6582  
goli.samimi@nih.gov

---

**RFA-CA-20-046**  
*National Cancer Institute*  
**Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01 Clinical Trial Optional)**  
**Deadline:** 12/15/2020  

**About:** Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to advance our understanding of: the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the cancer prevention and treatment strategies. It is not the intent of this FOA to fund follow-up translational and functional studies, but rather to enable the cancer research community to develop a new generation of studies that will leverage the genomic findings from NCI programs for the benefit of cancer patients. NCI project data, both ongoing and completed, will provide a unique reference resource on cancer-specific genomic aberrations for the cancer research community at large.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are limited to $300,000/year in direct costs, but need to reflect the actual needs of the proposed project.

**Program Contact:** Jean C. ZenKlusen  
(301) 451-2144  
jz44m@nih.gov
initial steps of infection; and the risk factors for infection. Such studies should inform and advance efforts to reduce or eliminate KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of HIV infection.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets should reflect the actual needs of the proposed project. Application budgets may not exceed $500,000 direct costs per year

**Program Contact:** Rebecca Liddell Huppi  
(240) 781-3324  
liddellr@exchange.nih.gov

---

**RFA-CA-20-045**

**National Cancer Institute**

**Limited Competition: International Agency for Research on Cancer (IARC) Monographs Program (R01 Clinical Trial Not Allowed)**

**Deadline:** 12/16/2020


**About:** This limited competition Funding Opportunity Announcement (FOA) solicits the renewal application for the International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Hazards to Humans. The IARC Monographs program, which is supported in part by the NCI, critically evaluates the published scientific evidence on carcinogenic hazards to humans. Monograph volumes are considered critical references that inform health policy and cancer research worldwide about carcinogenic hazards to reduce cancer burden globally.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** The application budget is limited to $793,135 in direct costs per year and should reflect the actual needs of the project.

**Program Contact:** Ron Johnson  
(240) 276-6250  
rjohnso2@mail.nih.gov